RAPT Therapeutics shares are trading lower after JP Morgan maintained an Overweight rating on the stock but lowered its price target from $39 to $32.
Portfolio Pulse from Benzinga Newsdesk
JP Morgan has maintained an Overweight rating on RAPT Therapeutics but lowered its price target from $39 to $32, causing the company's shares to trade lower.
August 16, 2023 | 4:26 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
RAPT Therapeutics' shares are trading lower after JP Morgan maintained an Overweight rating but lowered its price target from $39 to $32.
The lowering of the price target by JP Morgan, a major financial institution, indicates a less optimistic outlook for RAPT Therapeutics. This has led to a decrease in the company's share price as investors adjust their expectations.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100